Early Signals

Explore the emerging innovations, behaviours, and market shifts shaping the future of health, wellness, and fitness, turning fragmented early signals into structured foresight before they become obvious to the wider market.

To receive early signals weekly in your inbox, sign up to our newsletter, The Pulse.

Sector

Select
Sectors

Sub Sector

Select
Sub Sectors
More

Macro Trends

Select
Macro Trend
More

Micro Trends

Select
Micro Trend
More

Signal Type

Select
Signal Type
More

Signal Region

Select
Region
More

Membership Level

Membership Level

Date Range

Select Date

Vicore and Alex reported positive pilot results for a CBT-based digital therapeutic designed to support anxiety in idiopathic pulmonary fibrosis patients. The signal points toward digital therapeutics moving beyond broad wellness use cases into disease-linked mental health support, where clinical need, pathway clarity and measurable outcomes are easier to define.

Mental Well-being
New Evidence, Product / Platform
Free

Lilly has reported Phase 3 data for Foundayo, its oral GLP-1 candidate orforglipron, ahead of the ADA Scientific Sessions, positioning it as an oral incretin therapy without food or water restrictions. The signal points toward a more scalable, choice-led phase of obesity and diabetes treatment, where delivery format becomes a major adoption driver.

Medical & Pharma
New Evidence, Product / Platform
Free

Lucis has raised $20m to scale its AI-powered preventive health platform across Europe, combining 110-plus blood biomarkers with personalised guidance, while Cardio Diagnostics is positioning precision cardiovascular testing in the employer benefits market. Together, the signal suggests blood biomarkers are being repackaged from clinical diagnostics into AI-led prevention, consumer engagement and population-risk management.

Digital Health & Fitness, Medical & Pharma
New Evidence, Product / Platform
Free

PolyBio has launched the VIPER programme to validate biomarkers for Long COVID, aiming to establish objective biological measures for diagnosis and research. The initiative signals growing efforts to move Long COVID from a symptom-defined condition toward a biomarker-supported clinical category.

Medical & Pharma
Funding, New Evidence, Regulatory
Free

SPRIND has opened applications for a Continuous Hormone Monitoring challenge, funding teams to develop sensors that can measure at least four hormones continuously over seven days. The signal points toward hormone monitoring moving beyond static lab tests and fertility tracking into a more ambitious infrastructure layer for women’s health, endocrine care and personalised prevention.

Digital Health & Fitness, Medical & Pharma
Funding, Infrastructure, New Evidence
Free

Nike and Hyperice have launched the Hyperboot, a wearable recovery boot combining active heat and compression in footwear form. The signal points toward recovery moving from static at-home devices into wearable performance products designed for warm-up, readiness and everyday athlete routines.

Fitness & Exercise, Personal Care & Recovery
Behavioural, Partnerships, Product / Platform
Free